Medtech

Game-changing non-invasive diagnostic solutions to be showcased at MEDICA

Published

on

UK-based diagnostics technology company TestCard will unveil its cutting-edge non-invasive diagnostic solutions at MEDICA 2023.

The tech has been designed to make testing more accessible for consumers and in clinical settings.

As a participant in the ABHI UK Pavilion, Testcard will highlight how its technology transforms a mobile device into a clinical-grade scanner, revolutionising the field of diagnostics.

TestCard’s Chief Scientific Officer Dr. Andrew Botham said: “Rapid diagnostic testing helps to ease the pressures on health systems.

“Test results can be generated sooner and acted upon immediately, while mitigating risk for everyone. It also improves the patient pathway with a more effective patient triage, reducing delays with test results.”

At MEDICA 2023, TestCard will showcase its three primary areas of focus.

This includes the at-home UTI test kit, which boasts accuracy comparable to urine tests performed in clinical settings.

When combined with the smartphone app, it allows users to obtain immediate accurate test results from the comfort of their own home.

The tech directly integrates with individual suppliers to maintain a complete end-to-end pathway, back to the supplier for treatment.

Testcard has also developed advanced technical solutions for patient screening, helping to identify individuals at risk of serious illnesses.

By streamlining the process and enabling at-risk patients to test at home, healthcare providers can promptly allocate resources to those in need, helping to optimise GP and laboratory time.

In collaboration with Guys & St Thomas NHS Foundation Trust (GSTT), TestCard has launched the revolutionary ClearScreen technology that digitalises point of care rapid diagnostic testing including lateral flow tests.

The ClearScreen app immediately records patients’ test results digitally and transmits them to the EPR in seconds, meaning the result is available to all clinical teams in real time.

The company’s expanding test portfolio includes Single Covid, Covid/Flu dual test, Covid/Flu/RSV Triple test, Single RSV, Pregnancy, Strep A, CRP, D-Dimer, Troponin, and Monkeypox, contributing to quicker, more efficient healthcare pathways.

Its platform technology is currently in partnership with Superdrug, the NHS and Roche Diagnostics

Dr Botham added: “Testcard is excited to be joining ABHI at MEDICA 2023 to showcase our cutting-edge range of technologies designed to transform the fast-growing field of diagnostics, and we look forward to connecting with partners in the region.”

MEDICA is taking place from November 13-16 in Messe Düsseldorf, Germany.

To learn more about Testcard and explore the benefits of partnership, visit their booth at the ABHI UK Pavilion – Hall 16 Stand 16J60.5.

For more information, visit https://testcard.com/

Click to comment

Trending stories

Exit mobile version